In a report released yesterday, Joanne Wuensch from Citi upgraded Tandem Diabetes Care to a Hold, with a price target of $10.35.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joanne Wuensch’s rating is based on a combination of factors that reflect the current state of Tandem Diabetes Care’s stock. The company has experienced a significant decline in its share price, approximately 34% since its second-quarter 2025 report, where management adjusted expectations for new U.S. pumpers to flat or slightly down year-over-year. This adjustment has altered the risk/reward profile of the stock, bringing it closer to the lower end of the target price range.
Despite facing competitive pressures and ongoing investments in its product pipeline, the stock is trading at a low valuation relative to its historical levels. This valuation suggests a potential for seller exhaustion or acquisition interest, as seen in comparable company transactions. Consequently, the recommendation was upgraded to Neutral/High Risk from Sell/High Risk, with a slight increase in the target price, indicating that the current price level might be a suitable point for investors to reconsider their positions.
Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Tandem Diabetes Care. According to TipRanks, Wuensch has an average return of 6.3% and a 61.08% success rate on recommended stocks.
In another report released yesterday, Lake Street also initiated coverage with a Hold rating on the stock with a $12.00 price target.